BioSpace News Archive

Drug Development

Patient Death Pauses Another AML Trial

Following the death of a patient, Magenta Therapeutics placed a hold on Phase I/II dose-escalation trial of its acute myeloid leukemia therapy.

January 26, 2023
·
2 min read
·
Tristan Manalac
Drug Development

AC Immune Expands Vaccine Candidate to Down Syndrome

Phase I/II data showed AC Immune’s anti-amyloid-beta vaccine candidate could safely elicit an antibody response in patients with Alzheimer’s disease. Now, it will expand to Down Syndrome patients.

January 26, 2023
·
2 min read
·
Tristan Manalac
Study Predicts Higher Prevalence of VEXAS Syndrome (Updated)

A study published Tuesday in JAMA revealed VEXAS, a little-known syndrome with a high mortality rate, has a higher prevalence than previously thought.

January 26, 2023
·
2 min read
·
Kate Goodwin
Drug Development

Ocuphire to Advance Diabetic Retinopathy Drug Despite Missed Primary Endpoint

Ocuphire Pharma’s oral diabetic retinopathy drug missed the primary endpoint of an improvement in patient scores on the diabetic retinopathy severity scale.

January 26, 2023
·
2 min read
·
Hayley Shasteen
Business

Sartorius with clear double-digit growth in fiscal 2022

Following extraordinary growth in 2020 and 2021, the life science group Sartorius again outperformed the market in fiscal 2022, achieving its targets for sales revenue and profitability.

January 26, 2023
·
13 min read
Business

Preliminary results 2022 of Sartorius Stedim Biotech

Following extraordinary growth in 2020 and 2021, Sartorius Stedim Biotech, a leading partner of the biopharma industry, again outperformed the market in fiscal 2022.

January 26, 2023
·
11 min read
SN BioScience and Boryung Announce the Licensing Agreement on Generic Version of Abraxane

SN BioScience and Boryeong signed a domestic manufacturing technology transfer and co-development contract for the albumin nanoparticle anticancer drug developed by SN BioScience for the first time in Korea and the fourth time in the world.

January 26, 2023
·
3 min read
Business

Novozymes delivers historically strong full-year results

In the 2022 financial year, Novozymes delivers 9% organic sales growth – 11% organic sales growth in the fourth quarter alone – an EBIT-margin before special items[*] of 26.4%, and ROIC including goodwill before special items* of 17.9%.

January 26, 2023
·
4 min read
Business

Report on Operations 2022

Net sales amounted to SEK 131.5 million (85.9), corresponding to an increase of 53 percent in SEK and 34 percent adjusted for currency effects. Organic growth accounted for 27 percent and acquired growth for 7 percent.

January 26, 2023
·
5 min read
Evotec Announces Agreement with Janssen to Develop Immune-Based Therapies

Evotec SE announced that the Company has entered into a strategic collaboration and licence agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

January 26, 2023
·
4 min read